Technologies useful for clinical research in inhaled and nasal drug delivery development
Strados Labs supports inhalation and nasal drug development with its innovative wearable device that remotely measures respiratory symptoms associated with chronic lung diseases. The RESP® Biosensor, FDA-cleared, allows drug developers to objectively monitor cough levels in daily life as well as lung sounds including wheeze, rhonchi and crackles. Patient-friendly and wireless, the RESP Biosensor collects respiratory data that can reveal adverse patient reactions during pre-clinical drug testing such as severe cough. The technology is also used in phases I – IV clinical trials to strengthen evidence for treatment efficacy.
Would you like to list your company in this section or upgrade your existing listing? For information about supplier listing options, click here.